These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 15048071)

  • 41. Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma.
    Luminari S; Marcheselli L; Sacchi S; Pozzi S; Bari A; Ilariucci F; Stelitano C; Angrilli F; Lazzaro A; Baldini L
    Cancer; 2009 May; 115(9):1906-13. PubMed ID: 19248044
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.
    Fischer K; Cramer P; Busch R; Stilgenbauer S; Bahlo J; Schweighofer CD; Böttcher S; Staib P; Kiehl M; Eckart MJ; Kranz G; Goede V; Elter T; Bühler A; Winkler D; Kneba M; Döhner H; Eichhorst BF; Hallek M; Wendtner CM
    J Clin Oncol; 2011 Sep; 29(26):3559-66. PubMed ID: 21844497
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study.
    Österborg A; Jewell RC; Padmanabhan-Iyer S; Kipps TJ; Mayer J; Stilgenbauer S; Williams CD; Hellmann A; Furman RR; Robak T; Hillmen P; Trnêný M; Dyer MJ; Piotrowska M; Kozak T; Gupta IV; Phillips JL; Goldstein N; Struemper H; Losic N; Lisby S; Wierda WG;
    Haematologica; 2015 Aug; 100(8):e311-4. PubMed ID: 25769539
    [No Abstract]   [Full Text] [Related]  

  • 44. Oral high-dose glucocorticoids and ofatumumab in fludarabine-resistant chronic lymphocytic leukemia.
    Spaner DE
    Leukemia; 2012 May; 26(5):1144-5. PubMed ID: 22064354
    [No Abstract]   [Full Text] [Related]  

  • 45. A pilot monocentric analysis of efficacy and safety of Fludarabine-Campath combination (Flucam) as first line treatment in elderly patients with chronic lymphocytic leukaemia and Tp53 disfunction.
    Cencini E; Sozzi E; Sicuranza A; Fabbri A; Raspadori D; Lauria F; Forconi F
    Br J Haematol; 2011 Jul; 154(2):271-4. PubMed ID: 21521181
    [No Abstract]   [Full Text] [Related]  

  • 46. Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucémies et Autres Maladies du Sang (GOELAMS).
    Morschhauser F; Mounier N; Sebban C; Brice P; Solal-Celigny P; Tilly H; Feugier P; Fermé C; Copin MC; Lamy T
    Cancer; 2010 Sep; 116(18):4299-308. PubMed ID: 20549824
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Progressive multifocal leukoencephalopathy after treatment with rituximab, fludarabine and cyclophosphamide in a patient with chronic lymphocytic leukemia.
    Herold T; Seiler T; Egensperger R; Trumm C; Bergmann M; Franke D; Mumm FF; Schinwald N; Buske C; Dreyling M
    Leuk Lymphoma; 2012 Jan; 53(1):169-72. PubMed ID: 21812535
    [No Abstract]   [Full Text] [Related]  

  • 48. Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients.
    Zinzani PL; Pellegrini C; Broccoli A; Gandolfi L; Stefoni V; Casadei B; Maglie R; Argnani L; Pileri S
    Hematol Oncol; 2015 Sep; 33(3):141-6. PubMed ID: 24986783
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia.
    Foon KA; Mehta D; Lentzsch S; Kropf P; Marks S; Lenzner D; Pietragallo L; Sulecki M; Tarhini A; Boyiadzis M
    Blood; 2012 Mar; 119(13):3184-5. PubMed ID: 22461474
    [No Abstract]   [Full Text] [Related]  

  • 50. Treatment of refractory fludarabine induced autoimmune haemolytic with the anti-CD20 monoclonal antibody rituximab.
    Swords R; Nolan A; Fay M; Quinn J; O'Donnell R; Murphy PT
    Clin Lab Haematol; 2006 Feb; 28(1):57-9. PubMed ID: 16430461
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Direct antiglobulin test negative autoimmune haemolytic anaemia associated with fludarabine/cyclophosphamide/rituximab therapy.
    Garratty G; Petz LD
    Br J Haematol; 2007 Nov; 139(4):622-3. PubMed ID: 17979948
    [No Abstract]   [Full Text] [Related]  

  • 52. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia.
    Foon KA; Boyiadzis M; Land SR; Marks S; Raptis A; Pietragallo L; Meisner D; Laman A; Sulecki M; Butchko A; Schaefer P; Lenzer D; Tarhini A
    J Clin Oncol; 2009 Feb; 27(4):498-503. PubMed ID: 19075274
    [TBL] [Abstract][Full Text] [Related]  

  • 53. What choices are available for treatment of the patient with chronic lymphocytic leukemia who is fludarabine-refractory?
    Byrd JC; Rai KR
    Semin Oncol; 2000 Aug; 27(4):xii-xv; discussion xv-xvi. PubMed ID: 10950363
    [No Abstract]   [Full Text] [Related]  

  • 54. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.
    Robak T; Dmoszynska A; Solal-Céligny P; Warzocha K; Loscertales J; Catalano J; Afanasiev BV; Larratt L; Geisler CH; Montillo M; Zyuzgin I; Ganly PS; Dartigeas C; Rosta A; Maurer J; Mendila M; Saville MW; Valente N; Wenger MK; Moiseev SI
    J Clin Oncol; 2010 Apr; 28(10):1756-65. PubMed ID: 20194844
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy.
    Ysebaert L; Gross E; Kühlein E; Blanc A; Corre J; Fournié JJ; Laurent G; Quillet-Mary A
    Leukemia; 2010 Jul; 24(7):1310-6. PubMed ID: 20463751
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pentostatin treatment combinations in chronic lymphocytic leukemia.
    Lamanna N; Kay NE
    Clin Adv Hematol Oncol; 2009 Jun; 7(6):386-92. PubMed ID: 19606074
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma: experience on 142 patients.
    Zinzani PL; Pellegrini C; Broccoli A; Casadei B; Argnani L; Pileri S
    Am J Hematol; 2013 Nov; 88(11):E273-6. PubMed ID: 23843267
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Fludarabine plus rituximab for untreated B-cell chronic lymphocytic leukemia.
    Castagna L; Sarina B; Santoro A
    Blood; 2003 Sep; 102(6):2309; author reply 2309-10. PubMed ID: 12959942
    [No Abstract]   [Full Text] [Related]  

  • 59. Severe infusion-related reactions are uncommon in rituximab-treated CLL patients in clinical practice: results from a Swedish national observational study.
    Norin S; Björkstrand B; Rommel F; Timberg L; Andersson PO; Häggström J; Aldrin A; Hansson L
    Leuk Res; 2015 Jan; 39(1):33-7. PubMed ID: 25499233
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Individualized fludarabine-based regimen in elderly patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Guo B; Zhu HL; Fan H; Li SX; Lu XC; Lin J; Ran HH; Zhai B; Yang Y
    Adv Ther; 2012 Feb; 29(2):178-86. PubMed ID: 22249944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.